Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis

NCT07477639 is registered in ClinicalTrials.gov with Tr1X, Inc. as lead sponsor.

NCT NCT07477639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07477639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects With Primary or Secondary Progressive Multiple Sclerosis
Lead sponsor
Tr1X, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 1, 2026
Completion date
January 31, 2029
Enrollment
39 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, multiple sclerosis (ms) primary progressive, multiple sclerosis (ms) secondary progressive, primary progressive multiple sclerosis, secondary progressive multiple sclerosis (spms)